Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.91 |
| ▸ | RAF1 | P04049 | 8/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.58 |
| ▸ | GCGR | P47871 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856388 | 0.89 | BRAF (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7643418 | 0.84 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL29355176 | 0.84 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| Bromide SCHEMBL7648283 | 0.82 | BRAF (0.95) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7648286 | 0.80 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL28398004 | 0.79 | MAPK13 (0.77) | BRAFRAF1CYP19A1MAPK13MAPK12 | |
| SCHEMBL15075705 | 0.79 | MAPK14 (0.70) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL15075635 | 0.79 | MAPK14 (0.78) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL2649589 | 0.76 | MAPK13 (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL9736817 | 0.76 | MAPK13 (0.71) | BRAFRAF1CYP19A1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | BRAF 2006/4885RAF1 1509/4885CYP19A1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.